ID

38199

Descripción

Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification; ODM derived from: https://clinicaltrials.gov/show/NCT02177175

Link

https://clinicaltrials.gov/show/NCT02177175

Palabras clave

Versiones (2)
  1. 26/9/19 26/9/19 -
  2. 26/9/19 26/9/19 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

26 de septiembre de 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Breast Cancer NCT02177175

Inglés

Eligibility Breast Cancer NCT02177175

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
female
Descripción

Gender

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0079399
age ≥ 18 years
Descripción

Age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
non-metastatic histologically confirmed primary invasive breast carcinoma
Descripción

Invasive carcinoma of breast | Neoplasm Metastasis Absent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0853879
UMLS CUI [2,1]
C0027627
UMLS CUI [2,2]
C0332197
pathologically confirmed her2-positive breast cancer
Descripción

HER2-positive carcinoma of breast

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1960398
scheduled to receive anthracycline chemotherapy followed by anti-her2 therapy at mskcc
Descripción

Chemotherapy Scheduled | Anthracyclines | HER2 Targeted Therapy

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0392920
UMLS CUI [1,2]
C0205539
UMLS CUI [2]
C0282564
UMLS CUI [3,1]
C0069515
UMLS CUI [3,2]
C2985566
able and willing to provide informed consent
Descripción

Informed Consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
willing and able to comply with the requirements of the protocol
Descripción

Protocol Compliance

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0525058
able to swallow capsules
Descripción

Able to swallow capsules

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C2712086
UMLS CUI [1,2]
C0006935
for aim 2, all patients must meet the following criteria:
Descripción

Criteria Fulfill

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0243161
UMLS CUI [1,2]
C1550543
meet all inclusion criteria above
Descripción

Inclusion criteria Fulfill

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1512693
UMLS CUI [1,2]
C1550543
lvef > 50%
Descripción

Left ventricular ejection fraction

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0428772
abnormal global longitudinal strain (<19%, or a % decrease of ≥ 11% from baseline) prior to initiation of planned anti-her2 therapy
Descripción

Longitudinal strain rate.diastole.max Abnormal | Longitudinal strain rate.systole.max Abnormal | Status pre-HER2 Targeted Therapy

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C4263402
UMLS CUI [1,2]
C0205161
UMLS CUI [2,1]
C4263410
UMLS CUI [2,2]
C0205161
UMLS CUI [3,1]
C0332152
UMLS CUI [3,2]
C0069515
UMLS CUI [3,3]
C2985566
heart rate ≥ 50 beats per minute
Descripción

Heart rate

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0018810
sitting systolic blood pressure > 90 mmhg
Descripción

Sitting systolic blood pressure

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1319893
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients are to be excluded from randomization for aim 2 of this study if they meet any of the following criteria:
Descripción

Criteria Fulfill

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0243161
UMLS CUI [1,2]
C1550543
current treatment with ace-inhibitors or beta blockers
Descripción

Angiotensin-Converting Enzyme Inhibitors | Adrenergic beta-1 Receptor Antagonists

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0003015
UMLS CUI [2]
C0304516
allergies or inability to tolerate beta blockers previously due to bradycardia, hypotension, or av block.
Descripción

ID.17

Tipo de datos

boolean

known history of nci ctcae (version 4.0) grade ≥ 2 symptomatic chf, myocardial infarction within 12 months prior to randomization, significant symptoms (grade ≥ 3) relating to left ventricular dysfunction, significant (moderate or severe) valvular disease, or significant cardiac arrhythmia (grade ≥ 3)
Descripción

ID.18

Tipo de datos

boolean

pre-menopausal women without a negative serum or urine pregnancy test within 4 weeks of starting treatment
Descripción

ID.19

Tipo de datos

boolean

already enrolled in a breast cancer medicine therapeutic intervention trial
Descripción

ID.20

Tipo de datos

boolean

Volver a la parte superior de la página

Similar models

Eligibility Breast Cancer NCT02177175

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Gender
Item
female
boolean
C0079399 (UMLS CUI [1])
Age
Item
age ≥ 18 years
boolean
C0001779 (UMLS CUI [1])
Invasive carcinoma of breast | Neoplasm Metastasis Absent
Item
non-metastatic histologically confirmed primary invasive breast carcinoma
boolean
C0853879 (UMLS CUI [1])
C0027627 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
HER2-positive carcinoma of breast
Item
pathologically confirmed her2-positive breast cancer
boolean
C1960398 (UMLS CUI [1])
Chemotherapy Scheduled | Anthracyclines | HER2 Targeted Therapy
Item
scheduled to receive anthracycline chemotherapy followed by anti-her2 therapy at mskcc
boolean
C0392920 (UMLS CUI [1,1])
C0205539 (UMLS CUI [1,2])
C0282564 (UMLS CUI [2])
C0069515 (UMLS CUI [3,1])
C2985566 (UMLS CUI [3,2])
Informed Consent
Item
able and willing to provide informed consent
boolean
C0021430 (UMLS CUI [1])
Protocol Compliance
Item
willing and able to comply with the requirements of the protocol
boolean
C0525058 (UMLS CUI [1])
Able to swallow capsules
Item
able to swallow capsules
boolean
C2712086 (UMLS CUI [1,1])
C0006935 (UMLS CUI [1,2])
Criteria Fulfill
Item
for aim 2, all patients must meet the following criteria:
boolean
C0243161 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
Inclusion criteria Fulfill
Item
meet all inclusion criteria above
boolean
C1512693 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
Left ventricular ejection fraction
Item
lvef > 50%
boolean
C0428772 (UMLS CUI [1])
Longitudinal strain rate.diastole.max Abnormal | Longitudinal strain rate.systole.max Abnormal | Status pre-HER2 Targeted Therapy
Item
abnormal global longitudinal strain (<19%, or a % decrease of ≥ 11% from baseline) prior to initiation of planned anti-her2 therapy
boolean
C4263402 (UMLS CUI [1,1])
C0205161 (UMLS CUI [1,2])
C4263410 (UMLS CUI [2,1])
C0205161 (UMLS CUI [2,2])
C0332152 (UMLS CUI [3,1])
C0069515 (UMLS CUI [3,2])
C2985566 (UMLS CUI [3,3])
Heart rate
Item
heart rate ≥ 50 beats per minute
boolean
C0018810 (UMLS CUI [1])
Sitting systolic blood pressure
Item
sitting systolic blood pressure > 90 mmhg
boolean
C1319893 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Criteria Fulfill
Item
patients are to be excluded from randomization for aim 2 of this study if they meet any of the following criteria:
boolean
C0243161 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
Angiotensin-Converting Enzyme Inhibitors | Adrenergic beta-1 Receptor Antagonists
Item
current treatment with ace-inhibitors or beta blockers
boolean
C0003015 (UMLS CUI [1])
C0304516 (UMLS CUI [2])
ID.17
Item
allergies or inability to tolerate beta blockers previously due to bradycardia, hypotension, or av block.
boolean
ID.18
Item
known history of nci ctcae (version 4.0) grade ≥ 2 symptomatic chf, myocardial infarction within 12 months prior to randomization, significant symptoms (grade ≥ 3) relating to left ventricular dysfunction, significant (moderate or severe) valvular disease, or significant cardiac arrhythmia (grade ≥ 3)
boolean
ID.19
Item
pre-menopausal women without a negative serum or urine pregnancy test within 4 weeks of starting treatment
boolean
ID.20
Item
already enrolled in a breast cancer medicine therapeutic intervention trial
boolean
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial